OVARIAN NEOPLASMS

This phase 3 study tests whether adding two drugs (dostarlimab and niraparib) to standard chemotherapy helps people with advanced ovarian cancer live longer without their cancer growing. About 1,400 participants with stage III or IV ovarian cancer will receive either the new comb…

This early-stage study tests an experimental drug called SGN-MesoC2 in people with advanced solid tumors (like lung, ovarian, or pancreatic cancer) that have not responded to standard treatments. The drug is designed to attach to cancer cells and kill them. The main goals are to …

This study tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a marker called HER2. The drug is designed to stick to cancer cells and kill them. About 120 participants will receive the drug ev…

This early-stage study tests an experimental pill, ATV-1601, in people with advanced solid tumors (including certain breast, ovarian, and prostate cancers) that have a specific AKT1 gene mutation. The main goals are to check the drug's safety, find the best dose, and see how the …

This study tests a personalized immunotherapy called Vigil in 92 women with advanced ovarian cancer who are currently cancer-free after surgery and chemotherapy. The treatment uses the patient's own tumor cells to train the immune system to fight any remaining cancer cells. The m…

This study tests a drug called niraparib as a long-term maintenance treatment for people with advanced ovarian cancer (stage III or IV) who have finished initial chemotherapy and had a good response. The goal is to see if taking niraparib can delay the cancer from coming back. Ab…

This study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …

This study collects blood or saliva samples from people with cancer and their relatives to build a DNA bank. Researchers will use these samples to study how genes may increase the risk of developing certain cancers. About 992 participants are expected. No treatment or direct bene…